By removing the barrier of data collection, researchers will focus on figuring out what the data means.
In a moment that reflects medicine's slow turn toward collective knowledge, the International Progressive MS Alliance has opened a vast repository of patient data to the global research community. MS CIDR — drawn from 14 clinical trials and representing over 13,000 lives — offers scientists something rare: the accumulated evidence of years of observation, freely pooled rather than siloed. The initiative asks whether the hardest problems in progressive MS might yield faster not to more data collection, but to more minds working on the data already gathered.
- Progressive MS remains one of neurology's most stubborn frontiers, with limited treatments and a disease course that still resists clear prediction.
- MS CIDR breaks open a trove of 52,000 MRI scans and nearly 200,000 clinical visit records — data that individual research teams might spend years assembling on their own.
- Applications are open only through June 17, 2026, creating a narrow window for researchers to stake their claim on one of the largest MS datasets ever assembled.
- Strict eligibility rules — no drug comparisons, no commercial use without pre-authorization, no off-topic research — keep the resource tightly focused on understanding how the disease actually progresses.
- The model charges fees rather than offering free access, threading a careful line between openness and sustainability for both academic and industry partners.
On May 5, 2026, the International Progressive MS Alliance launched MS CIDR, a clinical and imaging data resource built from 14 major pharmaceutical trials and representing more than 13,000 patients living with multiple sclerosis. The collection includes roughly 52,000 MRI scans of the brain and spinal cord alongside records from nearly 200,000 clinical visits — a scale of evidence that few individual research programs could hope to match.
The alliance designed the resource around a single animating question: how does MS actually progress? To that end, eligible projects must focus on natural history modeling, the relationships between imaging and biomarker data, outcome measurement, or digital disease simulation. Researchers cannot use the data to pit one drug against another, and commercial applications are barred unless the alliance grants explicit prior approval.
Applications are accepted through June 17, 2026. Academic institutions pay a one-time project fee; industry partners operate under three-year contracts covering multiple studies. The costs are deliberate — sustaining the resource while keeping it accessible to legitimate science.
What MS CIDR represents, beyond its contents, is a philosophical wager: that pooling completed trial data and directing many minds toward it will outpace the old model of each team collecting its own evidence in isolation. For a disease where progress has been slow and the underlying biology remains incompletely understood, the alliance is betting that removing the barrier of data collection will free researchers to wrestle with the harder question — what the data, at last assembled, actually means.
A coalition of researchers and pharmaceutical companies has assembled one of the largest collections of multiple sclerosis patient data ever made available to the scientific community. The MS Clinical and Imaging Data Resource, or MS CIDR, opened its doors to applications on May 5, 2026, offering researchers access to anonymized information drawn from 14 major drug trials conducted over years of clinical work.
The dataset is substantial. It contains roughly 52,000 magnetic resonance imaging scans—the detailed brain and spinal cord pictures that show how MS damages the nervous system over time. Alongside those images sit records from nearly 200,000 clinical visits, the appointments where doctors examined patients, ran tests, and tracked their symptoms. All of this information comes from more than 13,000 people living with MS, most of them enrolled in studies designed to test new treatments for the progressive forms of the disease.
The International Progressive MS Alliance, the organization behind the resource, built MS CIDR specifically to answer one question: how does MS actually progress? The data is restricted to researchers working in academic institutions and pharmaceutical companies—not the general public, not for-profit ventures seeking to commercialize findings. The goal is to accelerate the pace of discovery by giving scientists access to real patient information they might otherwise spend years collecting themselves.
Researchers interested in using the data have until June 17, 2026, to submit applications. The process is straightforward in principle: applicants describe what they want to study, and the alliance determines whether the project fits within the resource's scope. Studies that map the natural history of disease—how MS unfolds in untreated patients or those on placebo—are welcome. Research exploring the relationships between imaging findings, blood biomarkers, and patient outcomes is encouraged. Projects that use the data to build digital simulations of disease progression or to develop new ways of measuring how sick patients are also qualify.
But there are clear boundaries. Researchers cannot use MS CIDR to compare how well different drugs work against each other, even through simulation or mathematical modeling. Projects unrelated to MS are excluded. And commercial ventures are off-limits unless the alliance grants special permission in advance and signs additional agreements.
Access comes with a cost. Academic researchers pay a one-time fee per project. Industry scientists and companies work under three-year contracts that allow them to pursue multiple studies during that period. The exact fees depend on the nature of the work and are detailed in the application materials.
The creation of MS CIDR represents a shift in how medical research operates. Rather than each team collecting its own patients, running its own trials, and hoarding data, this model pools resources from completed studies and makes them available to anyone with a legitimate research question. For a disease like progressive MS—where treatments are limited and the underlying biology remains poorly understood—that kind of data sharing could compress years of work into months. The alliance is betting that by removing the barrier of data collection, researchers will focus their energy on the harder problem: figuring out what the data actually means.
Notable Quotes
MS CIDR aims to accelerate the understanding of MS progression and speed up clinical trials aimed at finding solutions for progressive MS— International Progressive MS Alliance
The Hearth Conversation Another angle on the story
Why does a database of old clinical trial data matter now? Aren't there always new trials happening?
Yes, but new trials take years to design, recruit for, and complete. MS CIDR lets researchers ask new questions of data that's already been collected. They don't have to wait for patients to enroll or for scans to be done. They can start analyzing tomorrow.
But if the data comes from drug trials, isn't it biased toward people who were sick enough to enroll in those studies?
That's a real limitation, and researchers will know it. But 13,000 patients across 14 trials is still a massive sample. You can see patterns in disease progression that you'd never spot in a single trial of a few hundred people.
The restrictions seem pretty tight—no drug comparisons, no commercialization. Why lock it down like that?
Because the alliance wants to protect the integrity of the data and the trust of the patients who participated. If companies could use it to market drugs or make profits without contributing back, the whole system breaks down. The restrictions keep the focus on science.
Who actually benefits from this? The researchers, obviously. But what about patients?
Patients benefit indirectly. Better understanding of how MS progresses means better treatments eventually. But there's also a direct benefit: researchers might discover that certain imaging patterns predict who will get worse, which could change how doctors monitor patients today.
So this is really about speed. Getting answers faster than the old way.
Exactly. And about not making researchers reinvent the wheel. The data exists. The question is whether you let it sit in a vault or put it to work.